Radium-223 + abiraterone acetate: a potential safety issue

Bayer is to unblind data early from an ongoing randomized clinical trial of radium-223 acetate — on the guidance of the trial’s Independent Data Monitoring Committee (IDMC). … READ MORE …

This may put the cat among the pigeons!

A large, newly published, observational study has suggested that comorbidity affects other-cause mortality but not prostate cancer-specific mortality after accounting for patient and tumor characteristics and treatment type. … READ MORE …

Alternative medicine in the treatment of cancer (prostate cancer included)

There are very few good and thorough clinical studies on the use and the long-term effectiveness or efficacy of alternative forms of medicine in the treatment of cancer (let alone the treatment of prostate cancer specifically). … READ MORE …

This isn’t nice … it isn’t “fair” … but it’s true … and it’s important …

According to an article from Kaiser Health News on the CNN web site today, “People with advanced cancer don’t know enough about their disease to make informed decisions about treatment or how they want to spend their remaining time.” … READ MORE …

Time to death among men with nmCRPC by NCCN risk group

One of the abstracts to be presented at ASCO this year gives us some insight into risk for and time to death among men with non-metastatic but castration-resistant prostate cancer (nmCRPC). … READ MORE …

Aspirin use and risk for lethal prostate cancer

New data derived from the Physicans’ Health Study have suggested that there is an association between regular aspirin use and avoidance of risk for lethal forms of prostate cancer. … READ MORE …

Estimating overall survival for prostate cancer patients

It’s a question every prostate cancer patient wants an answer to: “OK doc. I get it. But how long am I gonna live with this?”

It’s also a question that doctors have a very great deal of difficulty answering, for a whole bunch of reasons. So … READ MORE …